Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.75 Contact Hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Foundation Medicine, Inc., Genentech, Lilly, Loxo Oncology, Inc., Merck Sharp & Dohme Corp., and Pfizer.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

19th Annual International Lung Cancer Congress®

19th Annual International Lung Cancer Congress®


July 26 - 28, 2018
Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA
Reservation: (888) 421-1442


Overview

The 19th Annual International Lung Cancer Congress® will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery, and radiation oncology in the clinic. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Foundation Medicine, Inc., Genentech, Lilly, Loxo Oncology, Inc., Merck Sharp & Dohme Corp., and Pfizer.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.


Target Audience

This educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.


Learning Objectives

  • Apply testing strategies to identify biomarkers that inform optimized decision-making in the care of patients with lung cancer
  • Determine emerging evidence concerning the management of patients with non-metastatic lung cancer
  • Delineate the rationale for optimized and personalized sequencing strategies utilizing clinical trial evidence, performance status, and tumor characteristics
  • Detail how recent clinical trial results on chemotherapeutic, targeted, and immunotherapeutic strategies can be interpreted in the context of evolving paradigms in the field of lung cancer management
  • Incorporate recent data sets on single agent and combination immunotherapeutic approaches to care for patients with lung cancer
  • Report the current status of cooperative group trials that are assessing emerging strategies to treat lung cancer


Program Directors

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA


Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT







Become a Member

Forgot Password?
Filter By